576 related articles for article (PubMed ID: 30115121)
1. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS
Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121
[TBL] [Abstract][Full Text] [Related]
2. Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.
Morley KC; Kranzler HR; Luquin N; Jamshidi N; Adams C; Montebello M; Tremonti C; Dali G; Logge W; Baillie A; Teesson M; Trent R; Haber PS
Am J Psychiatry; 2024 May; 181(5):403-411. PubMed ID: 38706338
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
4. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
Oslin DW; Leong SH; Lynch KG; Berrettini W; O'Brien CP; Gordon AJ; Rukstalis M
JAMA Psychiatry; 2015 May; 72(5):430-7. PubMed ID: 25760804
[TBL] [Abstract][Full Text] [Related]
5. An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.
Lin Y; Kranzler HR; Farrer LA; Xu H; Henderson DC; Zhang H
Pharmacogenomics J; 2020 Oct; 20(5):672-680. PubMed ID: 32029903
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
[TBL] [Abstract][Full Text] [Related]
7. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
[TBL] [Abstract][Full Text] [Related]
8. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
Kranzler HR; Armeli S; Covault J; Tennen H
Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013
[TBL] [Abstract][Full Text] [Related]
9. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Ray LA; Hutchison KE
Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
[TBL] [Abstract][Full Text] [Related]
11. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
Schacht JP; Randall PK; Latham PK; Voronin KE; Book SW; Myrick H; Anton RF
Neuropsychopharmacology; 2017 Dec; 42(13):2640-2653. PubMed ID: 28409564
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
Falk DE; O'Malley SS; Witkiewitz K; Anton RF; Litten RZ; Slater M; Kranzler HR; Mann KF; Hasin DS; Johnson B; Meulien D; Ryan M; Fertig J;
JAMA Psychiatry; 2019 Apr; 76(4):374-381. PubMed ID: 30865232
[TBL] [Abstract][Full Text] [Related]
14. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial.
O'Malley SS; Robin RW; Levenson AL; GreyWolf I; Chance LE; Hodgkinson CA; Romano D; Robinson J; Meandzija B; Stillner V; Wu R; Goldman D
Alcohol Clin Exp Res; 2008 Jul; 32(7):1271-83. PubMed ID: 18482155
[TBL] [Abstract][Full Text] [Related]
15. GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink.
Kranzler HR; Armeli S; Feinn R; Tennen H; Gelernter J; Covault J
Int J Neuropsychopharmacol; 2014 Oct; 17(10):1549-56. PubMed ID: 24786948
[TBL] [Abstract][Full Text] [Related]
16. Posttreatment effects of topiramate treatment for heavy drinking.
Kranzler HR; Wetherill R; Feinn R; Pond T; Gelernter J; Covault J
Alcohol Clin Exp Res; 2014 Dec; 38(12):3017-23. PubMed ID: 25581656
[TBL] [Abstract][Full Text] [Related]
17. Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder.
Kranzler HR; Morris PE; Pond T; Crist RC; Kampman KM; Hartwell EE; Lynch KG
Neuropsychopharmacology; 2021 Jul; 46(8):1407-1413. PubMed ID: 33568796
[TBL] [Abstract][Full Text] [Related]
18. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.
Kim SG; Kim CM; Choi SW; Jae YM; Lee HG; Son BK; Kim JG; Choi YS; Kim HO; Kim SY; Oslin DW
Psychopharmacology (Berl); 2009 Jan; 201(4):611-8. PubMed ID: 18795264
[TBL] [Abstract][Full Text] [Related]
19. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
[TBL] [Abstract][Full Text] [Related]
20. Comparing topiramate with naltrexone in the treatment of alcohol dependence.
Baltieri DA; DarĂ³ FR; Ribeiro PL; de Andrade AG
Addiction; 2008 Dec; 103(12):2035-44. PubMed ID: 18855810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]